慢性心力衰竭的药物治疗新进展

New Progress in Drug Therapy of Chronic Heart Failure

在原有慢性心脏疾病基础上出现心衰症状、体征的为慢性心衰。近些年来,临床技术以及医疗水平在不断提升,传统治疗慢性心力衰竭患者,一般会采用扩血管药物、强心类药物、利尿剂等药物进行治疗,可以有效改善患者的临床症状。随着临床医疗科技地逐渐发展,药物种类也在不断增多,药物治疗结果也在逐渐提高,治疗目标也从改善临床症状向心肌重构机制转变,以神经内分泌抑制疗法进一步的缓解并避免慢性心衰患者发生心肌重构,可以有效降低患者的病死率,缩短住院时间,减轻心衰症状,延长生存期,提高生活质量,防止疾病进展。心力衰竭依据左心射血分数(LVEF)可以分为三种类型:射血分数降低的心衰(HFrEF)、射血分数处于中间范围的心衰(HFmrEF)和射血分数保留的心衰(HFpEF)。本次研究针对以上三种类型,对药物治疗的新进展进行研究分析。

On the basis of the original chronic heart disease,the symptoms and signs of heart failure are chronic heart failure.In recent years,the clinical technology and medical level are constantly improving,traditional treatment of patients with chronic heart failure will generally use vasodilator,cardiotonic drugs,diuretics and other drugs for treatment,which can effectively improve the clinical symptoms of patients.With the gradual development of clinical medical science and technology,the types of drugs are also increasing,the results of drug treatment are gradually improving,and the treatment goal is also changing from improving clinical symptoms to myocardial remodeling mechanism.Neuroendocrine inhibition therapy can further alleviate and avoid myocardial remodeling in patients with chronic heart failure,which can effectively reduce the mortality of patients,shorten the length of hospital stay,and reduce heart failure symptoms,prolong the survival period,improve the quality of life,prevent disease progression.Heart failure can be divided into three types according to LVEF:heart failure with reduced ejection fraction(HFrEF),heart failure with ejection fraction in the middle range(HFmrEF)and heart failure with preserved ejection fraction(HFpEF).In this study,According to the above three types,the new progress of drug treatment was analyze.